ℹ️ Compiled from public regulatory records · Last regulator revision: May 29, 2026🚩 Report this page

Idarubicin

Anthracyclines and Related Substances

GB MHRACA Health Canada

Drug class: Anthracyclines and Related Substances
Availability: See label
Routes: Intravenous
Markets covered: 2
Products on record: 8

L01DBAnthracyclines and Related Substances

Overview

Idarubicin is an active pharmaceutical ingredient in the Anthracyclines and Related Substances group (L01DB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	7	May 29, 2026
CA Canada	Health Canada	1	July 16, 2025

GBUnited Kingdom· MHRA

7 products

Uses

GBOfficial regulatory label· revised May 1, 2026[1]

Cytotoxic and antimitotic agent. Adults - For the treatment of acute myeloid leukaemia (AML), for remission induction in untreated patients or for remission induction in relapsed or refractory patients. - For second line treatment of relapsed acute lymphoblastic leukaemia (ALL).
Children - For first line treatment of acute myeloid leukaemia (AML), in combination with cytarabine, for remission induction. - For second line treatment of relapsed acute lymphoblastic leukaemia (ALL). 2).

How to take

CACanada· Health Canada

1 product

Uses

CAOfficial regulatory label· revised July 16, 2025[2]

IDARUBICIN (idarubicin hydrochloride injection) is indicated, alone or in combination chemotherapy regiments involving other cytotoxic agents, for: • Acute non-lymphocytic leukemia (ANLL); in adults for remission induction as front-line therapy or for remission induction in relapsed or refractory patients.
• Acute lymphocytic leukemia (ALL) as second line treatment in adults and children. 1 Pediatrics Pediatrics (age range not specified): IDARUBICIN is indicated in acute lymphocytic leukemia (ALL) as second line treatment in children.
2 Geriatrics Geriatrics (≥ 60 years): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Patients over 60 years of age who were undergoing induction therapy experienced congestive heart failure, serious arrhythmias, chest pain, myocardial infarction, and asymptomatic declines in LVEF more frequently than younger patients.

Drug interactions

Known interactions involving Idarubicin. Select one for details. This list is informational and not a complete interaction checker.

Adalimumab Amiodarone Amisulpride Anagrelide Arsenic Trioxide Baricitinib Bedaquiline Bepridil Cabozantinib Ceritinib Certolizumab Pegol Chloroquine Cisapride Citalopram Cladribine Clozapine Crizotinib Deferiprone Disopyramide Dofetilide Dolasetron Dronedarone Droperidol Efavirenz Escitalopram Etanercept Fingolimod Gatifloxacin Golimumab Grepafloxacin Halofantrine Haloperidol Hydroxychloroquine Ibutilide Iloperidone Infliximab Ivabradine Ivosidenib Lefamulin Leflunomide Lumefantrine Macimorelin Mesoridazine Methadone Mifepristone Moxifloxacin Natalizumab Nilotinib Osimertinib Ozanimod Panobinostat Papaverine Pasireotide Pimozide Procainamide Quinidine Ribociclib Saquinavir Selpercatinib Siponimod Sotalol Sparfloxacin Teriflunomide Thalidomide Thioridazine Tofacitinib Toremifene Trastuzumab Upadacitinib Vandetanib Vemurafenib Ziprasidone Abarelix Abiraterone Adenosine Albuterol Aldesleukin Alefacept Alemtuzumab Alfuzosin Alpelisib Amitriptyline Amoxapine Anakinra Apalutamide Apomorphine Arformoterol Aripiprazole Asenapine Astemizole Atomoxetine Atorvastatin Azathioprine Azithromycin Bendamustine Bicalutamide Bleomycin Boceprevir Brigatinib Buprenorphine Busulfan Canakinumab Candida Albicans Capecitabine Capmatinib Carboplatin Carmustine Chlorambucil Chloramphenicol Chlorpromazine Cilostazol Ciprofloxacin Cisplatin Clarithromycin Clofarabine Clofazimine Clomipramine Coccidioides Immitis Spherule Conivaptan Cyclophosphamide Cyclosporine Cytarabine Dacarbazine Daclatasvir Dactinomycin Dasatinib Daunorubicin Decitabine Degarelix Delavirdine Denosumab Desipramine Deutetrabenazine Diltiazem Dimethyl Fumarate Diroximel Fumarate Docetaxel Donepezil Doxepin Doxorubicin Efalizumab Elagolix Eliglustat Encorafenib Entrectinib Enzalutamide Epirubicin Erdafitinib Eribulin Erythromycin Etoposide Ezogabine Famotidine Felodipine Filgrastim Flecainide Flibanserin Floxuridine Fluconazole Fludarabine Fluorouracil Fluoxetine Fluphenazine Flutamide Formoterol Foscarnet Fostamatinib Fostemsavir Galantamine Ganciclovir Gemcitabine Gemifloxacin Gilteritinib Glasdegib Glecaprevir Goserelin Granisetron Halothane Histrelin Hydroxyurea Hydroxyzine Idelalisib Ifosfamide Imatinib Imipramine Indacaterol Inotuzumab Ozogamicin Interferon Alfa-2b Isatuximab Isavuconazonium Isoetharine Isoproterenol Istradefylline Itraconazole Ivacaftor Ketoconazole Lactobacillus Acidophilus Lapatinib Lasmiditan Lenvatinib Leuprolide Levofloxacin Lisdexamfetamine Lithium Carbonate Lofexidine Lomitapide Lomustine Loperamide Lovastatin Lurbinectedin Maprotiline Mechlorethamine Mefloquine Melphalan Mercaptopurine Metaproterenol Methotrexate Methotrimeprazine Midostaurin Mirtazapine Mitomycin Mitoxantrone Monomethyl Fumarate Naxitamab Nefazodone Nelarabine Nelfinavir Neratinib Nifedipine Nilutamide Niraparib Norfloxacin Nortriptyline Ocrelizumab Ofloxacin Olanzapine Olaparib Oliceridine Olodaterol Omacetaxine Mepesuccinate

Showing 240 of 343. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL200750526 · revised May 1, 2026
[2]Health Canada (DPD) · 02410028 · revised July 16, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.